MCL1 and neoplasm: The balance of Bcl-2/Mcl-1 proteins has also been largely shown to impact the efficacy of ABT-737 [34]–[36], [41], [42], suggesting that modulation of Noxa and Mcl-1 could be used as a strategy for sensitizing tumor cells to ABT-737 [31], [43].